#1 Clinical Trials Search in Europe

Immunglobulin

This article discusses a clinical trial investigating the use of imlifidase and immunoglobulin in kidney transplantation for highly sensitized children. The trial aims to evaluate the effectiveness and safety of these treatments in improving transplant success rates for children with end-stage renal disease who have difficulty finding suitable donor kidneys due to their immune system’s high sensitivity.

Table of Contents

What is IMMUNGLOBULIN?

IMMUNGLOBULIN, also known as immunoglobulin, is a type of medication derived from blood plasma containing antibodies[1]. These antibodies are proteins that help your body fight against infections and diseases. In the context of kidney transplantation, IMMUNGLOBULIN is being studied as a potential treatment to help highly sensitized children receive kidney transplants more successfully.

Medical Conditions Treated

The clinical trial is focusing on using IMMUNGLOBULIN to treat highly sensitized pediatric patients who are waiting for a kidney transplant[1]. Being “highly sensitized” means that these children have developed antibodies against a wide range of potential donor organs, making it very difficult to find a suitable match for transplantation.

Specifically, the trial is looking at patients with:

  • End-stage renal disease (ESRD): A condition where the kidneys have stopped working well enough for the patient to survive without dialysis or a kidney transplant.
  • Positive crossmatch: This means that the patient’s immune system is likely to reject the donor kidney.
  • High levels of panel reactive antibodies (PRA): A measure of how sensitized a patient is, with 80% or higher considered highly sensitized[1].

How IMMUNGLOBULIN Works

IMMUNGLOBULIN is being studied as part of a treatment protocol to help reduce the body’s immune response against donor kidneys. The goal is to convert a positive crossmatch (which indicates a high risk of rejection) to a negative crossmatch, potentially allowing for successful transplantation[1].

In this study, IMMUNGLOBULIN is used in combination with other medications to prepare the patient’s immune system for the transplant. It’s important to note that this is an experimental approach, and its effectiveness is still being evaluated.

Clinical Trial Details

The clinical trial is designed to evaluate the safety and effectiveness of IMMUNGLOBULIN in combination with other medications for kidney transplantation in highly sensitized children. Some key aspects of the trial include:

  • It’s a single-arm, multi-centre trial, meaning all participants receive the same treatment.
  • The study includes children aged 1 to 17 years.
  • The main goal is to see if the treatment can convert a positive crossmatch to negative within 24 hours[1].
  • Researchers will monitor kidney function, survival rates, and potential complications for up to 5 years after transplantation.

Eligibility Criteria

To participate in this study, patients must meet certain criteria, including:

  • Age between 1 and 17 years
  • Diagnosis of end-stage renal disease
  • High sensitization (PRA ≥80%)
  • Positive crossmatch against a potential donor kidney
  • Previous unsuccessful desensitization attempts or deemed too difficult for successful desensitization[1]

There are also several exclusion criteria, such as previous treatment with imlifidase, certain infections, and ongoing serious medical conditions.

Potential Benefits

If successful, this treatment approach could offer several benefits:

  • Increased chances of finding a suitable donor kidney
  • Reduced risk of organ rejection
  • Improved kidney function after transplantation
  • Better long-term survival rates for both the patient and the transplanted kidney[1]

Safety and Side Effects

As with any medical treatment, there are potential risks and side effects. The study will closely monitor participants for:

  • Infusion-related reactions
  • Infections
  • Changes in laboratory test results
  • Other adverse events[1]

The safety of IMMUNGLOBULIN and the other medications used in this protocol will be carefully evaluated throughout the study.

Other Medications Used in the Study

In addition to IMMUNGLOBULIN, the study protocol includes several other medications:

  • Rituximab: A medication that targets certain immune cells
  • Methylprednisolone: A corticosteroid to suppress the immune system
  • Anti-human T-lymphocyte immunoglobulin: Another medication to modulate the immune response[1]

These medications work together to prepare the patient’s immune system for the transplant and reduce the risk of rejection.

Aspect Details
Study Type Single-arm, multi-centre clinical trial
Target Population Highly sensitized children (1-17 years) needing kidney transplant
Main Treatment Imlifidase and Immunoglobulin
Primary Objective Evaluate crossmatch conversion with imlifidase treatment
Key Secondary Objectives Assess renal function, antibody levels, graft survival, patient survival
Follow-up Duration Up to 5 years post-transplantation
Key Inclusion Criteria PRA ≥80%, positive crossmatch, end-stage renal disease
Key Exclusion Criteria Previous imlifidase treatment, active infections, recent malignancy

FAQ

  • What is the main goal of this clinical trial? The main goal is to evaluate how well imlifidase treatment can convert a positive crossmatch test to negative within 24 hours, which is crucial for successful kidney transplantation in highly sensitized children.
  • Who can participate in this trial? Children aged 1 to 17 years with end-stage renal disease, who are highly sensitized (with panel reactive antibodies ≥80%) and waiting for a kidney transplant from a living or deceased donor can participate, subject to specific inclusion and exclusion criteria.
  • What treatments are being studied in this trial? The trial is studying the use of imlifidase, a drug designed to reduce antibodies that can cause rejection, and immunoglobulin, which helps modulate the immune system. These are used in combination with standard transplant medications.
  • How long will participants be followed in this study? Participants will be followed for up to 5 years after transplantation to assess long-term outcomes such as kidney function, graft survival, and overall patient survival.
  • What are some of the key things researchers will be measuring? Researchers will measure kidney function, donor-specific antibody levels, graft and patient survival, delayed graft function, drug levels in the body, and safety parameters including adverse events and infections.

Ongoing Clinical Trials on Immunglobulin

  • Study on Imlifidase and Drug Combination for Kidney Transplant in Highly Sensitized Children

    Recruiting

    2 1 1 1
    Investigated drugs:
    Finland France Spain Sweden

Glossary

  • Imlifidase: A drug designed to reduce antibodies in the body that can cause rejection of transplanted organs.
  • Immunoglobulin: A type of protein that acts as an antibody in the immune system. In this trial, it's used to help modulate the immune response.
  • Highly sensitized: Refers to patients whose immune systems have developed antibodies against a wide range of potential donors, making it difficult to find a suitable match for transplantation.
  • Crossmatch: A test to determine if a recipient has pre-existing antibodies against a potential donor's tissues. A positive crossmatch indicates a high risk of rejection.
  • Panel Reactive Antibodies (PRA): A measure of how reactive a recipient's immune system is against a panel of potential donors. A higher PRA percentage indicates a more sensitized patient.
  • End-stage renal disease (ESRD): Advanced kidney failure requiring dialysis or transplantation for survival.
  • Desensitization: A process to reduce the number of antibodies in a patient's body to improve the chances of successful transplantation.
  • Donor-specific antibodies (DSA): Antibodies in the recipient's body that react specifically against the donor's tissues.
  • Delayed graft function (DGF): A situation where the transplanted kidney does not function immediately after transplantation.
  • Glomerular filtration rate (eGFR): A measure of how well the kidneys are filtering waste from the blood.

References

  1. http://clinicaltrials.eu/trial/study-on-imlifidase-and-drug-combination-for-kidney-transplant-in-highly-sensitized-children/